通过额外的权威和用户费用推进FDA的人类食品计划
Jennifer L Pomeranz1, Sean B Cash2, Emily Broad Leib3
1Jennifer L. Pomeranz (jlp284@nyu.edu), New York University, New York, New York.
Health affairs (Project Hope)
|April 7, 2025
概括
食品和药物管理局 (FDA) 需要更多的资源和权力来确保食品安全,特别是超加工食品. 一个新的用户收费计划可以为加强监督提供必要的资金.
科学领域:
- 食品安全法规 食品安全法规
- 公共卫生政策 公共卫生政策
- 监管科学 监管科学
背景情况:
- 美国食品和药物管理局 (FDA) 在确保食品安全和适当标签方面面临资源限制和权力缺口.
- 对食品成分的市场前后监督存在重大担忧,特别是超加工食品中的食品成分.
- 许多食品成分缺乏足够的安全数据,或者FDA和公众都不知道.
研究的目的:
- 分析FDA现有的与食品相关的当局,以寻找潜在的用户收费计划实施.
- 确定新的或增强的用户费用可以加强FDA监督能力的政策领域.
- 评估食品监管综合性用户收费计划的可行性和潜在益处.
主要方法:
- 美国食品和药物管理局目前与食品有关的当局的法律和政策分析.
- 审查其他FDA监管领域的成功用户收费计划.
- 审查政策领域适合新的或增强的用户费用.
主要成果:
- 美国食品和药物管理局 (FDA) 的食品相关部门可以接受新的用户费用计划.
- 用户费用可以产生有针对性的资源,以解决关键的监督差距.
- 一个全面的食品用户收费计划可以使行业和公共卫生受益.
结论:
- 加强FDA的权威和资源对于通过提高食品安全来保护公共健康至关重要.
- 一个精心设计的用户费用计划提供了一个可行的机制,为FDA的食品计划提供必要的资金.
- 实施食品用户收费计划可以加强FDA确保安全,健康和适当标记食品的能力.
相关概念视频
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
01:11Clinical Trials: Overview
2.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.6K
01:03Drug Control Governance: Regulatory Bodies and Their Impact
129
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
129
01:28Preclinical Development: Overview
4.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.1K
01:19Pharmacovigilance
756
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
756
01:17Drug Nomenclature
1.5K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.5K